New and Novel Therapies for Gynecologic Cancers

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Objective: To review recent therapies approved by the US Food and Drug Administration for the treatment of gynecologic malignancies. Data sources: PubMed, FDA.gov, ASCO.org. Conclusion: The landscape for treating gynecologic malignancies is rapidly changing. Maintenance therapy now exists for women with advanced ovarian cancer after completing chemotherapy for both newly diagnosed and platinum-sensitive recurrent ovarian cancer. Anti-angiogenic therapy has many applications in gynecologic malignancies. Immunotherapy can be used in certain situations for women with gynecologic malignancies. Implications for Nursing Practice: Biologic agents and immunotherapy have distinct side-effect profiles that nurses need to be aware of to optimize patient care and outcomes.

Original languageEnglish (US)
JournalSeminars in Oncology Nursing
DOIs
StatePublished - Jan 1 2019
Externally publishedYes

Fingerprint

Ovarian Neoplasms
Immunotherapy
Neoplasms
Information Storage and Retrieval
Biological Factors
United States Food and Drug Administration
Therapeutics
Platinum
PubMed
Patient Care
Nursing
Nurses
Drug Therapy

Keywords

  • bevacizumab
  • cervical cancer
  • endometrial cancer
  • ovarian cancer
  • parp inhibitors
  • pembrolizumab

ASJC Scopus subject areas

  • Oncology(nursing)

Cite this

New and Novel Therapies for Gynecologic Cancers. / Richardson, Debra L.

In: Seminars in Oncology Nursing, 01.01.2019.

Research output: Contribution to journalReview article

@article{474f5c7e57c5422fabc28edfd0fe2c53,
title = "New and Novel Therapies for Gynecologic Cancers",
abstract = "Objective: To review recent therapies approved by the US Food and Drug Administration for the treatment of gynecologic malignancies. Data sources: PubMed, FDA.gov, ASCO.org. Conclusion: The landscape for treating gynecologic malignancies is rapidly changing. Maintenance therapy now exists for women with advanced ovarian cancer after completing chemotherapy for both newly diagnosed and platinum-sensitive recurrent ovarian cancer. Anti-angiogenic therapy has many applications in gynecologic malignancies. Immunotherapy can be used in certain situations for women with gynecologic malignancies. Implications for Nursing Practice: Biologic agents and immunotherapy have distinct side-effect profiles that nurses need to be aware of to optimize patient care and outcomes.",
keywords = "bevacizumab, cervical cancer, endometrial cancer, ovarian cancer, parp inhibitors, pembrolizumab",
author = "Richardson, {Debra L}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.soncn.2019.02.009",
language = "English (US)",
journal = "Seminars in Oncology Nursing",
issn = "0749-2081",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - New and Novel Therapies for Gynecologic Cancers

AU - Richardson, Debra L

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Objective: To review recent therapies approved by the US Food and Drug Administration for the treatment of gynecologic malignancies. Data sources: PubMed, FDA.gov, ASCO.org. Conclusion: The landscape for treating gynecologic malignancies is rapidly changing. Maintenance therapy now exists for women with advanced ovarian cancer after completing chemotherapy for both newly diagnosed and platinum-sensitive recurrent ovarian cancer. Anti-angiogenic therapy has many applications in gynecologic malignancies. Immunotherapy can be used in certain situations for women with gynecologic malignancies. Implications for Nursing Practice: Biologic agents and immunotherapy have distinct side-effect profiles that nurses need to be aware of to optimize patient care and outcomes.

AB - Objective: To review recent therapies approved by the US Food and Drug Administration for the treatment of gynecologic malignancies. Data sources: PubMed, FDA.gov, ASCO.org. Conclusion: The landscape for treating gynecologic malignancies is rapidly changing. Maintenance therapy now exists for women with advanced ovarian cancer after completing chemotherapy for both newly diagnosed and platinum-sensitive recurrent ovarian cancer. Anti-angiogenic therapy has many applications in gynecologic malignancies. Immunotherapy can be used in certain situations for women with gynecologic malignancies. Implications for Nursing Practice: Biologic agents and immunotherapy have distinct side-effect profiles that nurses need to be aware of to optimize patient care and outcomes.

KW - bevacizumab

KW - cervical cancer

KW - endometrial cancer

KW - ovarian cancer

KW - parp inhibitors

KW - pembrolizumab

UR - http://www.scopus.com/inward/record.url?scp=85062599911&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062599911&partnerID=8YFLogxK

U2 - 10.1016/j.soncn.2019.02.009

DO - 10.1016/j.soncn.2019.02.009

M3 - Review article

C2 - 30876683

AN - SCOPUS:85062599911

JO - Seminars in Oncology Nursing

JF - Seminars in Oncology Nursing

SN - 0749-2081

ER -